Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion type Assertion NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_head.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion description "[We performed MethyLight analysis of the methylation status of 15 promoter CpG island loci involved in breast cancer progression (APC, DLEC1, GRIN2B, GSTP1, HOXA1, HOXA10, IGF2, MT1G, RARB, RASSF1A, RUNX3, SCGB3A1, SFRP1, SFRP4, and TMEFF2) and determined cancer stem cell phenotype by CD44/CD24 and ALDH1 immunohistochemistry in 36 luminal A, 33 luminal B, 30 luminal-HER2, 40 HER2 enriched, and 40 basal-like subtypes of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_provenance.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion evidence source_evidence_literature NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_provenance.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion SIO_000772 22037257 NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_provenance.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion wasDerivedFrom befree-20150227 NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_provenance.
- NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_assertion wasGeneratedBy ECO_0000203 NP876940.RArpDf3g5GB5WUbSqvxAAr6a4m49UqIwHA2gb6O1QFli4130_provenance.